Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies

Scott, Linda M. and Gandhi, Maher K. (2015) Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 29 6: 405-415. doi:10.1016/j.blre.2015.06.002

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ364649_OA.pdf Full text (open access) application/pdf 715.20KB 1

Author Scott, Linda M.
Gandhi, Maher K.
Title Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies
Journal name Blood Reviews   Check publisher's open access policy
ISSN 1532-1681
0268-960X
Publication date 2015
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.blre.2015.06.002
Open Access Status File (Author Post-print)
Volume 29
Issue 6
Start page 405
End page 415
Total pages 11
Place of publication London, United Kingdom
Publisher Churchill Livingstone
Collection year 2016
Language eng
Abstract Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma. In marked contrast to the situation in patients with either acute lymphoblastic leukaemia or a myeloproliferative neoplasm, JAK2 coding sequence mutations are rare in lymphoma patients with an activated JAK/STAT “signature”. This is instead the consequence of mutational events that result in the increased expression of non-mutated JAK2; positively or negatively affect the activity of other components of the JAK/STAT pathway; or establish an autocrine signalling loop that drives JAK-mediated cytokine-independent proliferation. Here, we detail these genetic lesions, their functional consequences, and impact on patient outcome. In light of the approval of a JAK1/JAK2 inhibitor for the treatment of myelofibrosis, and preliminary studies evaluating the efficacy of other JAK inhibitors, the therapeutic potential of compounds that target JAK/STAT signalling in the treatment of patients with lymphoma is also discussed.
Keyword JAK2
STAT signalling
Lymphoma
JAK inhibitors
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 14 Jul 2015, 01:45:11 EST by System User on behalf of UQ Diamantina Institute